NO301047B1 - Antihypertensive sammensetninger - Google Patents
Antihypertensive sammensetninger Download PDFInfo
- Publication number
- NO301047B1 NO301047B1 NO922903A NO922903A NO301047B1 NO 301047 B1 NO301047 B1 NO 301047B1 NO 922903 A NO922903 A NO 922903A NO 922903 A NO922903 A NO 922903A NO 301047 B1 NO301047 B1 NO 301047B1
- Authority
- NO
- Norway
- Prior art keywords
- pyridazodiazepine
- combination
- atoms
- blood pressure
- tetrahydronaphthalene derivative
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract description 11
- 230000003276 anti-hypertensive effect Effects 0.000 title abstract description 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 150000004677 hydrates Chemical class 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 9
- XUZYMNGRDVLZPI-KKXMJGKMSA-N Cl.Cl.N1=C(NC2=C1C=CC=C2)CCCN(CC[C@@]2([C@H](C1=CC=C(C=C1CC2)F)C(C)C)COCC(=O)O)C Chemical compound Cl.Cl.N1=C(NC2=C1C=CC=C2)CCCN(CC[C@@]2([C@H](C1=CC=C(C=C1CC2)F)C(C)C)COCC(=O)O)C XUZYMNGRDVLZPI-KKXMJGKMSA-N 0.000 claims description 3
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims 2
- 239000002585 base Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 4
- -1 alkyl radical Chemical class 0.000 abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 15
- 239000002966 varnish Substances 0.000 description 14
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 11
- 229960005025 cilazapril Drugs 0.000 description 11
- 229940126062 Compound A Drugs 0.000 description 10
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000007903 gelatin capsule Substances 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000004922 lacquer Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000005541 ACE inhibitor Substances 0.000 description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 description 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 5
- 230000004531 blood pressure lowering effect Effects 0.000 description 5
- 239000000480 calcium channel blocker Substances 0.000 description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
- 229960000830 captopril Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 241001515942 marmosets Species 0.000 description 3
- 229960005425 nitrendipine Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 229960004438 mibefradil Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- External Artificial Organs (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH219191 | 1991-07-23 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO922903D0 NO922903D0 (no) | 1992-07-22 |
| NO922903L NO922903L (no) | 1993-01-25 |
| NO301047B1 true NO301047B1 (no) | 1997-09-08 |
Family
ID=4228024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO922903A NO301047B1 (no) | 1991-07-23 | 1992-07-22 | Antihypertensive sammensetninger |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5620975A (enExample) |
| EP (1) | EP0524512B1 (enExample) |
| JP (1) | JPH0680009B2 (enExample) |
| KR (1) | KR100260479B1 (enExample) |
| CN (1) | CN1040505C (enExample) |
| AT (1) | ATE260661T1 (enExample) |
| AU (1) | AU656207B2 (enExample) |
| BG (1) | BG60949B1 (enExample) |
| BR (1) | BR9202830A (enExample) |
| CA (1) | CA2074039C (enExample) |
| CZ (1) | CZ281691B6 (enExample) |
| DE (1) | DE59209993D1 (enExample) |
| DK (1) | DK0524512T3 (enExample) |
| ES (1) | ES2215160T3 (enExample) |
| HR (1) | HRP930953B1 (enExample) |
| HU (1) | HU214029B (enExample) |
| IE (1) | IE922378A1 (enExample) |
| IL (1) | IL102541A (enExample) |
| IS (1) | IS3887A (enExample) |
| MX (1) | MX9204212A (enExample) |
| MY (1) | MY118064A (enExample) |
| NO (1) | NO301047B1 (enExample) |
| NZ (1) | NZ243577A (enExample) |
| PT (1) | PT524512E (enExample) |
| RO (1) | RO110905B (enExample) |
| RU (1) | RU2084225C1 (enExample) |
| SK (1) | SK278918B6 (enExample) |
| TW (1) | TW216770B (enExample) |
| UY (1) | UY23449A1 (enExample) |
| YU (2) | YU49198B (enExample) |
| ZA (1) | ZA925322B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE198551T1 (de) * | 1993-07-15 | 2001-01-15 | Hoffmann La Roche | Pharmazeutische kombination, die einen hemmer des renin-angiotensin-systems und einen endothelin- antagonisten enthält |
| IL131816A (en) | 1997-04-04 | 2003-06-24 | Exxon Res & Engineering Compan | Composite structures having high containment strength |
| US6608097B2 (en) | 2001-10-10 | 2003-08-19 | Aryx Therapeutics | Materials and methods for the treatment of hypertension and angina |
| US7687086B1 (en) | 2003-02-28 | 2010-03-30 | University Of Portland | Method for obtaining taxanes |
| RU2282443C1 (ru) * | 2004-12-29 | 2006-08-27 | Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" | Лекарственное средство, обладающее антигипертензивным действием, и способ его изготовления |
| EP2537534B1 (en) | 2011-06-22 | 2014-12-17 | Hexal AG | Esters of (1S,9S)-9-[[(1S)-1-carboxy-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid and their therapeutic use. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2128984B (en) * | 1982-05-12 | 1985-05-22 | Hoffmann La Roche | Diaza-bicyclic compounds |
| DE3542794A1 (de) * | 1985-12-04 | 1987-06-11 | Bayer Ag | Antihypertensives kombinationspraeparat |
| DK171349B1 (da) * | 1986-11-14 | 1996-09-16 | Hoffmann La Roche | Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler |
| FR2607004B1 (fr) * | 1986-11-20 | 1990-06-01 | Synthelabo | Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine |
| US5110813A (en) * | 1987-09-15 | 1992-05-05 | Alcoholism And Drug Addiction Research Foundation | Reduction of voluntary alcohol consumption by treatment with angiotensin converting enzyme inhibitors |
| US4871731A (en) * | 1987-10-07 | 1989-10-03 | Marion Laboratories, Inc. | Captopril and diltiazem composition and the like |
| KR940005408B1 (ko) * | 1990-12-03 | 1994-06-18 | 만도기계 주식회사 | 파워 윈도우 모우터 회전자의 선단부 흔들림 측정장치 |
-
1992
- 1992-07-04 TW TW081105301A patent/TW216770B/zh active
- 1992-07-11 AT AT92111847T patent/ATE260661T1/de not_active IP Right Cessation
- 1992-07-11 EP EP92111847A patent/EP0524512B1/de not_active Expired - Lifetime
- 1992-07-11 DK DK92111847T patent/DK0524512T3/da active
- 1992-07-11 DE DE59209993T patent/DE59209993D1/de not_active Expired - Fee Related
- 1992-07-11 ES ES92111847T patent/ES2215160T3/es not_active Expired - Lifetime
- 1992-07-11 PT PT92111847T patent/PT524512E/pt unknown
- 1992-07-16 ZA ZA925322A patent/ZA925322B/xx unknown
- 1992-07-16 NZ NZ243577A patent/NZ243577A/en unknown
- 1992-07-16 CA CA002074039A patent/CA2074039C/en not_active Expired - Fee Related
- 1992-07-17 IL IL10254192A patent/IL102541A/en not_active IP Right Cessation
- 1992-07-17 MX MX9204212A patent/MX9204212A/es active IP Right Grant
- 1992-07-20 HU HU9202367A patent/HU214029B/hu not_active IP Right Cessation
- 1992-07-20 AU AU20416/92A patent/AU656207B2/en not_active Ceased
- 1992-07-20 RU SU925052378A patent/RU2084225C1/ru not_active IP Right Cessation
- 1992-07-21 CZ CS922270A patent/CZ281691B6/cs not_active IP Right Cessation
- 1992-07-21 BG BG96664A patent/BG60949B1/bg unknown
- 1992-07-21 RO RO92-0990A patent/RO110905B/ro unknown
- 1992-07-21 KR KR1019920012932A patent/KR100260479B1/ko not_active Expired - Fee Related
- 1992-07-21 SK SK2270-92A patent/SK278918B6/sk unknown
- 1992-07-21 MY MYPI92001289A patent/MY118064A/en unknown
- 1992-07-22 NO NO922903A patent/NO301047B1/no not_active IP Right Cessation
- 1992-07-22 CN CN92108668A patent/CN1040505C/zh not_active Expired - Fee Related
- 1992-07-22 UY UY23449A patent/UY23449A1/es not_active IP Right Cessation
- 1992-07-22 IE IE237892A patent/IE922378A1/en not_active Application Discontinuation
- 1992-07-23 YU YU72392A patent/YU49198B/sh unknown
- 1992-07-23 JP JP4216629A patent/JPH0680009B2/ja not_active Expired - Fee Related
- 1992-07-23 IS IS3887A patent/IS3887A/is unknown
- 1992-07-23 YU YU72392A patent/YU72392A/sh unknown
- 1992-07-23 BR BR929202830A patent/BR9202830A/pt not_active Application Discontinuation
-
1993
- 1993-06-07 HR HR930953A patent/HRP930953B1/xx not_active IP Right Cessation
-
1994
- 1994-11-02 US US08/333,171 patent/US5620975A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Opdyke et al. | Response to angiotensins I and II and to AI-converting-enzyme inhibitor in a shark | |
| HK14494A (en) | Medicaments containing dipyridamol or mopidamol and o-acetylsalicylic acid, or its physiologically compatible salts, process for their manufacture and their use in combating the formation of thrombus | |
| RS52907B (sr) | Upotreba ace inhibitora za prevenciju kongestivne srčane insuficijencije | |
| HU221202B1 (en) | Synergetic pharmaceutical combination containing a benzolsulfonamid-derivative and cilazapril | |
| BROOKS et al. | Role of brain prostaglandins in the control of vasopressin secretion in the conscious rat | |
| CA2124445A1 (en) | Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine | |
| DE69632854T2 (de) | Schutzmittel für Organe und Gewebe | |
| EP0363671B1 (de) | Verwendung von ACE-Inhibitoren gegen Neointimabildung nach Gefässverletzung | |
| NO301047B1 (no) | Antihypertensive sammensetninger | |
| DE69132782T2 (de) | Verwendung von angiotensin-ii-antagonisten in der behandlung der linken ventrikulären hypertrophie | |
| US4705792A (en) | 4-amino-2-(imidazolidin-2-on-1-yl)-5-(3-trifluoromethyl-phenyllaminocarbonyl)pyrimidines for antithrombotic prophylaxis and treatment | |
| AU602867B2 (en) | Prostacyclines, their analogues or prostaglandines and thromboxane antagonists for the treatment of thrombotic and thrombo-embolic illnesses | |
| US3360434A (en) | Method for reducing blood pressure with phenylalanine derivatives | |
| FR2605884A1 (fr) | Nouvelle association medicamenteuse | |
| DE3627613A1 (de) | Pharmazeutische zubereitung | |
| DE68912432T2 (de) | Pharmazeutische Zusammensetzung, verwendbar bei der Behandlung von Herzgefässerkrankungen. | |
| BE896621A (fr) | Nouvelle utilisation therapeutique d'analogues de prostaglandines | |
| AU620132B2 (en) | Use of 2-azabicyclo(2.2.2) octane-3-carboxylic acid derivatives for the production of medicinal products intended for the treatment of diseases resulting from impairment of the vascular wall as well as for disorders of the microcirculation | |
| DE69832075T2 (de) | Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks | |
| MC2019A1 (fr) | Composition pharmaceutique anti-hypertensive combinee | |
| WO1999017756A2 (de) | Methode zur verhinderung der transplantatabstossung | |
| DE3915236A1 (de) | Pharmazeutische zubereitung | |
| RS68204A (sr) | Kombinovani preparat inhibitora natrijum-vodonik, izmene cariporida sa ace-inhibitorom za sprečavanje srčane insuficijencije i drugih disfunkcija organa prouzrokovanih starenjem,oboljenja prouzrokovanih starenjem i za produženje života | |
| GB2241890A (en) | Preventing onset of or treating protein catabolism using an ace inhibitor | |
| JPWO1993003715A1 (ja) | 血管肥厚抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |